开源证券维持信邦制药研报，公司信息更新报告：Q2利润增长提速，核心业务医疗服务成长潜力大

七印授权

1NW5NBXCGOJWJLOOMZ4WF9GPXX09HW9U3NIQNGD3RICP7TLOYE

2021-08-27 00:17:15

article

7F6DF13723E44AC7D00BA8126A782C8F4D95FF37B040226A324C51483538A5E9

zh-CN

C1544443810DE1F5A1709DFBC751FAD783CF99AA

10593956

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

08d25405896b18828afa9e1f7387796527398610385d9d2b6e86442b6b4e87467ab91d38de8ddd670280658efd5c930b612b64e1bf277b6d6c03c770dee7fa491c

{"parameters":{"adaptation":"n","price":"100000"},"type":"cm"}

yuanben_61282f0b1a8093.87459112

原本认证

https://www.yuanben.io/article/8e1cc542-e7dd-48f8-8698-b59969bc3f25

{"author":"每日经济新闻","authorization_pub_key":"03040cbbeae1adf91c3efd7306d09c6005403a041f9b7405dac489d4f8126fef8c"}